Pilot Study Investigating the Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer

Status: Completed
Location: See location...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable

See where the dye-like material (FACBC) goes in your body and how long it stays in your body. See how much of the dye-like material is picked up by your tumor Compare the FACBC pictures with other pictures (such as FDG PET scan) that were obtained as part of your standard imaging evaluation.

Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No

• Age ≥ or equal 18 years old

• Scheduled for treatment at Memorial Hospital

• Primary HNSCC or primary breast cancer; histological confirmation of diagnosis at Memorial hospital

• Large primary HNSCC cancer (loco-regional advanced, ≥ or equal to T2) by CT/MRI imaging or clinical exam, without prior treatment, N1-N3

• Large primary breast cancer (≥ or equal to T2) by imaging or clinical impression based physical exam; patients with suspicion of axillary nodal disease (N1-2), without prior treatment

• Established progressive metastatic prostate cancer

• This diagnosis may be based upon histologic confirmation of metastatic disease by biopsy of a lesion OR clear clinical evidence for metastatic disease (e.g., based on clinical findings, laboratory data and/or imaging findings in CT, MRI, or bone scan), as defined by the referring oncologist

• Progressive disease is defined as clear progression on imaging studies (increase in size and number of lesions on bone scan, CT, or MRI) and consecutive rises in PSA as used in clinical management by the prostate cancer oncology group at MSKCC

• FDG PET scan was obtained as part of the clinical work-up, within 4 weeks prior to enrollment. This clinical FDG PET scan should be done at MSKCC.

• Disease can be clearly demonstrated by structural imaging (CT or MRI) or bone scan. This may include characteristic bone lesions on bone scan, CT or MRI; AND/OR measurable soft tissue/nodal lesions on CT or MRI.

• Minimum tumor/metastasis size of 1 cm

• Negative pregnancy test

United States
New York
Memorial Sloan Kettering Cancer Center
New York
Time Frame
Start Date: April 25, 2006
Completion Date: April 6, 2017
Target number of participants: 20
Experimental: 1
Pet Scan
Related Therapeutic Areas
Leads: Memorial Sloan Kettering Cancer Center

This content was sourced from clinicaltrials.gov

Similar Clinical Trials